Loading…
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-284M | $-256M | $-233M | -28.3% | - | 40.5% |
| 2024 | $0M | $-217M | $-182M | $-172M | -25.4% | - | 116.9% |
| 2023 | $0M | $-93M | $-84M | $-75M | -22.1% | - | 111.1% |
| 2022 | $0M | $-31M | $-40M | $-16M | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 30.73 | 93 | 216.87 | 285.60 |
| Research And Development | 27.79 | 68.42 | 167.86 | 214.71 |
| Selling General And Administration | 2.94 | 24.58 | 49 | 69.75 |
| Total Expenses | 30.73 | 93 | 216.87 | 285.60 |
| Operating Income | -30.73 | -93 | -216.87 | -285.60 |
| Total Operating Income As Reported | -30.73 | -93 | -216.87 | -285.60 |
| EBITDA | -30.64 | -93 | -216.68 | -284.18 |
| Normalized EBITDA | -30.64 | -93 | -216.68 | -284.18 |
| EBIT | -30.64 | -93 | -216.87 | -285.60 |
| Interest Income | 0.09 | 9.02 | 34.74 | 30.03 |
| Interest Expense | 9.15 | 0 | - | - |
| Net Interest Income | -9.06 | 9.02 | 34.74 | 30.03 |
| Interest Income Non Operating | 0.09 | 9.02 | 34.74 | 30.03 |
| Interest Expense Non Operating | 9.15 | 0 | - | - |
| Net Non Operating Interest Income Expense | -9.06 | 9.02 | 34.74 | 30.03 |
| Pretax Income | -39.78 | -83.98 | -182.13 | -255.56 |
| Tax Provision | - | 0 | 0.02 | 0.28 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | -39.78 | -83.98 | -182.15 | -255.84 |
| Net Income From Continuing And Discontinued Operation | -39.78 | -83.98 | -182.15 | -255.84 |
| Net Income From Continuing Operation Net Minority Interest | -39.78 | -83.98 | -182.15 | -255.84 |
| Net Income | -39.78 | -83.98 | -182.15 | -255.84 |
| Net Income Common Stockholders | -39.78 | -83.98 | -182.15 | -255.84 |
| Net Income Including Noncontrolling Interests | -39.78 | -83.98 | -182.15 | -255.84 |
| Normalized Income | -39.78 | -83.98 | -182.15 | -255.84 |
| Diluted NI Availto Com Stockholders | -39.78 | -83.98 | -182.15 | -255.84 |
| Basic Average Shares | 27.25 | 25.01 | 55.19 | - |
| Diluted Average Shares | 27.25 | 25.01 | 55.19 | - |
| Reconciled Depreciation | - | 0 | 0.19 | 1.42 |
| Depreciation Amortization Depletion Income Statement | - | - | 0 | 1.13 |
| Depreciation And Amortization In Income Statement | - | - | 0 | 1.13 |
| General And Administrative Expense | 2.94 | 24.58 | 49 | 69.75 |
| Other Gand A | 1.30 | 24.58 | 18.70 | 19.12 |
| Salaries And Wages | 1.64 | 12.58 | 30.30 | 50.64 |
| Depreciation Income Statement | - | - | 0 | 1.13 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Apogee Therapeutics, Inc.this co. | APGE | $6.9B | -26.79 | 7.58 | -28.3% | -23.68 |
| HealthEquity, Inc. | HQY | $7.2B | 33.42 | 3.41 | 10.2% | 16.10 |
| Oscar Health, Inc. | OSCR | $7.1B | -16.06 | 7.28 | -45.3% | - |
| Vaxcyte, Inc. | PCVX | $7.0B | -9.18 | 2.62 | -28.5% | -7.77 |
| Spyre Therapeutics, Inc. | SYRE | $6.8B | - |
| 9.53 |
| -21.7% |
| - |
| Arcellx, Inc. | ACLX | $6.7B | -29.41 | 16.73 | -56.9% | -30.17 |
| Immunovant, Inc. | IMVT | $6.7B | -13.27 | 7.87 | -59.3% | -10.90 |
| Lantheus Holdings, Inc. | LNTH | $6.7B | 28.66 | 6.14 | 21.4% | 17.23 |
| Hims & Hers Health, Inc. | HIMS | $6.5B | 50.51 | 11.99 | 23.7% | 46.06 |
| Peer Median | - | -9.18 | 7.57 | -25.1% | 4.16 | |